Regeneus Ltd

Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain.

Pain and inflammation are responsible for a series of events leading to immune cells reacting to damaged tissue, causing chronic and acute illness.

The Company develops regenerative medicine products that interrupt the inflammatory cascade that leads to pain, including its two leading stem cell technologies, Progenza™ – which has been licenced to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus – which is in pre-clinical stage.

At Regeneus we pride ourselves in our ability to create research collaborations and further our knowledge to advance our therapies.

By creating scientific communities we have been able to advance our methods and quality selection criteria to obtain highly scalable and highly potent products.

Through scientific co-creation we are advancing the field of pain therapy and providing relief to millions of people around the world.

Regeneus has two lead platform technologies Progenza™ and Sygenus. Our technologies are supported by robust intellectual property and manufacturing capabilities.

We apply the technology to multiple indications. Our current therapeutic areas include knee osteoarthritis, neuropathic pain and skin inflammation. Progenza™ is a cryopreserved multi-synergistic therapy targeting pain and inflammation. Regeneus has patented techniques and high-quality testing to ensure the production of millions of Progenza™ doses from a single donor (allogeneic). A topical Secretome product. Sygenus contains the bioactive molecules from the Secretome to reduce pain and inflammation while accelerating tissue healing and repair. The safety and tolerability of Sygenus have been confirmed in human pilot studies.